Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
131.20    -0.40 (-0.30%)
Bid:
130.80
Ask:
131.20
Spread: 0.40 (0.306%)
Market Cap: £319.36m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Holding(s) in Company

8 May 2026 07:00

RNS Number : 5074D
PureTech Health PLC
08 May 2026
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BY2Z0H74

Issuer Name

PURETECH HEALTH PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Briarwood Chase Management LLC

City of registered office (if applicable)

New York

Country of registered office (if applicable)

USA

4. Details of the shareholder

Name

City of registered office

Country of registered office

Morgan Stanley & Co., LLC

New York

USA

5. Date on which the threshold was crossed or reached

06-May-2026

6. Date on which Issuer notified

07-May-2026

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

5.093400

0.000000

5.093400

12398267

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BY2Z0H74

12398267

5.093400

Sub Total 8.A

12398267

5.093400%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Aalap Mahadevia

5.093400

5.093400%

Briarwood Chase Management LLC

5.093400

5.093400%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

07-May-2026

13. Place Of Completion

New York, NY USA

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLARMBTMTBMTLF
Date   Source Headline
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:35 pmRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSFinal Results
1st Apr 20204:41 pmRNSSecond Price Monitoring Extn
1st Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20204:42 pmRNSSecond Price Monitoring Extn
27th Mar 20204:37 pmRNSPrice Monitoring Extension
24th Mar 202012:03 pmRNSPrice Monitoring Extension
20th Mar 202010:16 amRNSPrice Monitoring Extension
18th Mar 20204:42 pmRNSSecond Price Monitoring Extn
18th Mar 20204:37 pmRNSPrice Monitoring Extension
10th Mar 202010:00 amRNSGelesis: World’s Most Innovative Companies List
10th Mar 20207:00 amRNSNotice of Results
9th Mar 20204:41 pmRNSSecond Price Monitoring Extn
9th Mar 20204:36 pmRNSPrice Monitoring Extension
6th Mar 202012:02 pmRNSPrice Monitoring Extension
5th Mar 20204:40 pmRNSSecond Price Monitoring Extn
5th Mar 20204:35 pmRNSPrice Monitoring Extension
3rd Mar 20204:40 pmRNSSecond Price Monitoring Extn
3rd Mar 20204:36 pmRNSPrice Monitoring Extension
3rd Mar 202012:02 pmRNSPrice Monitoring Extension
3rd Mar 20207:00 amRNSClinical Trial Initiated Of Wholly-Owned Candidate
2nd Mar 20207:00 amRNSTotal Voting Rights
27th Feb 20204:41 pmRNSSecond Price Monitoring Extn
27th Feb 20204:36 pmRNSPrice Monitoring Extension
25th Feb 20207:00 amRNSAkili ADHD Study in The Lancet Digital Health
18th Feb 20207:00 amRNSPRTC to Present at Leerink Healthcare Conference
3rd Feb 20204:40 pmRNSSecond Price Monitoring Extn
3rd Feb 20204:35 pmRNSPrice Monitoring Extension
3rd Feb 20207:00 amRNSTotal Voting Rights
23rd Jan 20207:00 amRNSPureTech Receives $200M from KRTX Shares
15th Jan 20201:04 pmRNSAkili's New ADHD Trial Met Primary Endpoint
13th Jan 202012:07 pmRNSSecond Price Monitoring Extn
13th Jan 202012:02 pmRNSPrice Monitoring Extension
2nd Jan 20207:00 amRNSTotal Voting Rights
19th Dec 20197:00 amRNSFollica Positive Androgenetic Alopecia Study
17th Dec 201912:00 pmRNSGelesis Partners with US Telehealth Provider
12th Dec 20191:04 pmRNSAkili Meets Primary Endpoint in MDD Clinical Trial
10th Dec 201912:02 pmRNSPrice Monitoring Extension
10th Dec 20197:00 amRNSVedanta & BMS Begin Immuno-Oncology Clinical Study
9th Dec 20197:00 amRNSGelesis Attracts $84M in New Capital for Launch
5th Dec 20197:00 amRNSVedanta MultiDrug Resistance Program Granted $5.8M
2nd Dec 20197:00 amRNSTotal Voting Rights
25th Nov 201912:02 pmRNSPrice Monitoring Extension
21st Nov 20197:00 amRNSKaruna Prices $250M Follow-On Offering
18th Nov 201911:03 amRNSKaruna Successful Ph2 Schizophrenia Study Readout
15th Nov 201912:51 pmRNSresTORbio Update on Phase 3 Trial
13th Nov 20197:00 amRNSPureTech to Present at Jefferies London Conference
5th Nov 20191:00 pmRNSPRTC Presents Novel Oncology Program Data at SITC
5th Nov 201911:00 amRNSGelesis Shares New Plenity Safety & Efficacy Data

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.